EphA2

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10. Poster Presentation Details: Title: Bicycle Toxin Conjugates® for the treatment of solid tumors Session Title: Cancer Treatment: New Technologies Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET Abstract Number: 5807 Speaker/Lead Author: Stephen Walsh, Ph.D., Bicycle Therapeutics Title: Modulation of the natural killer cell immune response to tumor with a synthetic tumor-immune cell agonist, NK-TICA™ Session Title: CAR-NK, NK Engagers and NK Modulators Date and Time: Monday, April 8, at 9 a.m. PT/12 p.m. ET Abstract Number: 1340 Speaker/Lead Author: Fay Dufort, Ph.D., Bicycle Therapeutics Title: Tumor-targeted activation of CD137 using Bicycles: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2-expressing cancers Session Title: Immune Modulation Employing Agonist or Co-Stimulatory Approaches Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET Abstract Number: 5301 Speaker/Lead Author: Johanna Lahdenranta, Ph.D., Bicycle Therapeutics The posters will be made available in the Publications section of bicycletherapeutics.com following the presentations. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com. View source version on businesswire.com: Contacts Investors: Stephanie Yao SVP, Investor Relations and Corporate Communications ir@bicycletx.com 857-523-8544 Media: Argot Partners Deborah Elson media@bicycletx.com 212-600-1902 Source: Bicycle Therapeutics plc View this news release online at:

Using RNA sequencing and spatial transcriptomics, the roles of PKM gene and EPHA2 pathway in the development of HNSCC were discovered. BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined. Continue Reading The cellular diversity and structural attributes within the tumor microenvironment of HNSCC due to HPV viral infection needs to be ascertained. Using samples from both HPV negative and HPV positive patients for single-cell RNA profiling and spatial transcriptomics, the molecular characteristics of HNSCC were studied. In a novel and pioneering research work, a team of scientists led by Yun Hak Kim, Assistant Professor in the Department of Anatomy and Department of Biomedical Informatics at the School of Medicine at Pusan National University, Korea, has recently studied the cellular diversity and molecular attributes within the complex tumor microenvironment of HNSCC with respect to the status of HPV infection. Their research findings were recently published in the Journal of Medical Virology on 18 January 2024. "The incidence of HNSCC has gone up considerably in the recent years and yet very little is known about the exact molecular mechanisms regarding the role of HPV infection and its link with HNSCC," shares Dr. Kim, revealing the inspiration behind the present research work. Using samples from both HPV negative (HPV−) and HPV positive (HPV+) patients for single-cell RNA profiling, a genetic sequencing technique, and spatial transcriptomics (ST), an advanced molecular profiling technique, the primary tumors and lymph node metastatic tumors (LNMTs) were analyzed. The in-depth research findings provide remarkable imagery into the complex links between HPV infection and the development of HNSCC. In the case of HPV+ HNSCC, immune cells actively participated in the development of tumors. The molecular characteristics of HNSCC were highly influenced by the status of HPV infection rather than the actual location of tumor. The analyses of RNA sequencing and ST indicated the crucial role of pyruvate kinase muscle (PKM) gene in the development of cancer stem cell-like populations in the LNMT of HPV− tissue. In HPV− HNSCC cell lines, the expression of PKM gene was consistent and indicated a role in the spheroid structure formation ability, which was studied using genetic knockdown of PKM2 gene. Interestingly, during the ST analysis of the HPV+ patients, the presence of such ectopic lymphoid structure was confirmed. Dr. Kim and their team went a step further and focused their efforts to study the critical angiogenesis-new blood vessel formation pathway. They used single-cell RNA and ST profiles of HPV− patients and found that Ephrin-A (EPHA2) was mainly involved in angiogenesis and cell migration pathways. "Our novel research findings of PKM and EPHA2 molecular pathways can be utilized as therapeutic targets in suppressing the growth and spread of HNSCC cancer cells. Also, the tumor microenvironment is affected by the status of HPV infection and thus, precision medicine can be developed against HNSCC," concludes Dr. Kim, underlining the potential real-life applications of the research work. Overall, this study significantly enhances our understanding of HNSCC microenvironment. Thus, it can guide new approaches to HNSCC treatment, especially in inhibiting cancer cell growth and migration. Therefore, the HPV infection could be considered a criterion for developing treatment strategies, thereby enabling precision medicine tailored to the patient's condition! Reference Title of original paper: Deciphering Head and Neck Cancer Microenvironment: Single–Cell and Spatial Transcriptomics Reveals Human Papillomavirus–Associated Differences Journal: Journal of Medical Virology DOI: About Pusan National University Website: Contact: Jae-Eun Lee 82 51 510 7928 373618@email4pr.com SOURCE Pusan National University

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics Limited (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in March: TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024; fireside chat at 11:10 a.m. ET Leerink Partners Global Biopharma Conference on Monday, March 11, 2024; fireside chat at 12 p.m. ET Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024; fireside chat at 8:30 a.m. ET Live webcasts of the fireside chats will be accessible in the Investor section of the company’s website at . Archived replays of the webcasts will be available following the fireside chat dates. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.